Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 8;15(3):2356–2364. doi: 10.3892/etm.2018.5724

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Chen et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Pathological tissue section analysis of Anti-SEMA-7A efficacy of in rats with acute LPS-induced lung injury. (A) Therapeutic effects of Anti-SEMA-7A in rats with lung injury induced by LPS determined by the number of injury lung cells. Magnification, ×40. (B) SEMA-7A expression was analyzed in pathological tissue section following treatment with Anti-SEMA-7A. Magnification, ×40. (C) Analysis of IL-1β, IL-17A and TNF-α inflammatory factor expression from pathological tissue sections following Anti-SEMA-7A treatment. (D) Expression of chemokines CXCR2, MIP-2 and KC in pathological tissue section following Anti-SEMA-7A treatment. Anti-SEMA-7A, antibody for Semaphorin-7A; IL, interleukin; TNF-α, tumor necrosis factor-α; CXCR2, C-X-C motif chemokine receptor 2; MIP-2, macrophage inflammatory protein 2; LPS, lipopolysaccharide; KC, keratinocyte chemoattractant.